多药耐药铜绿假单胞菌肺炎治疗后亚胺培南-雷巴他定耐药的演变。
Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.
机构信息
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
出版信息
Clin Infect Dis. 2022 Sep 10;75(4):710-714. doi: 10.1093/cid/ciac097.
Abstract
We report the emergence of imipenem-relebactam nonsusceptible Pseudomonas aeruginosa in 5 patients treated for nosocomial pneumonia for 10-28 days. Genome sequence analysis identified treatment-emergent mutations in MexAB-OprM and/or MexEF-OprN efflux operons that arose independently in each patient across distinct P. aeruginosa sequence types. Testing with efflux-inhibitor PAβN restored imipenem-relebactam susceptibility.
摘要
我们报告了 5 例住院肺炎患者在接受治疗 10-28 天后出现对亚胺培南-雷巴他定不敏感的铜绿假单胞菌。基因组序列分析鉴定出 MexAB-OprM 和/或 MexEF-OprN 外排操纵子在每个患者中独立出现的治疗后突变，这些患者跨越不同的铜绿假单胞菌序列类型。用外排抑制剂 PAβN 进行测试恢复了亚胺培南-雷巴他定的敏感性。
相似文献
1
Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.
Clin Infect Dis. 2022 Sep 10;75(4):710-714. doi: 10.1093/cid/ciac097.
2
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
J Antimicrob Chemother. 2023 May 3;78(5):1195-1200. doi: 10.1093/jac/dkad062.
3
Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during exposure to ceftazidime/avibactam in .
Microbiol Spectr. 2025 Mar 4;13(3):e0231224. doi: 10.1128/spectrum.02312-24. Epub 2025 Feb 11.
4
Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.
J Antimicrob Chemother. 2022 Mar 31;77(4):957-968. doi: 10.1093/jac/dkab496.
5
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
J Antimicrob Chemother. 2022 Sep 30;77(10):2809-2815. doi: 10.1093/jac/dkac241.
6
In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022.
Int J Antimicrob Agents. 2025 Sep;66(3):107550. doi: 10.1016/j.ijantimicag.2025.107550. Epub 2025 Jun 4.
7
Activity of imipenem-relebactam, ceftolozane-tazobactam and comparators against clinical isolates of Enterobacterales and Pseudomonas aeruginosa causing severe infections in hematological and oncological patients: A prospective multicenter study.
Int J Antimicrob Agents. 2025 Sep;66(3):107534. doi: 10.1016/j.ijantimicag.2025.107534. Epub 2025 May 8.
8
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Int J Infect Dis. 2021 Dec;113:279-281. doi: 10.1016/j.ijid.2021.10.022. Epub 2021 Oct 17.
9
Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.
Diagn Microbiol Infect Dis. 2019 Oct;95(2):212-215. doi: 10.1016/j.diagmicrobio.2019.05.001. Epub 2019 May 8.
10
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Int J Antimicrob Agents. 2023 Apr;61(4):106744. doi: 10.1016/j.ijantimicag.2023.106744. Epub 2023 Feb 3.
引用本文的文献
1
Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.
Antibiotics (Basel). 2025 May 21;14(5):528. doi: 10.3390/antibiotics14050528.
2
Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel β-lactams in .
Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0194224. doi: 10.1128/aac.01942-24. Epub 2025 Mar 11.
3
Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during exposure to ceftazidime/avibactam in .
Microbiol Spectr. 2025 Mar 4;13(3):e0231224. doi: 10.1128/spectrum.02312-24. Epub 2025 Feb 11.
4
Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study).
Infect Dis Ther. 2025 Jan;14(1):283-292. doi: 10.1007/s40121-024-01077-z. Epub 2024 Nov 29.
5
Evolutionary loss of an antibiotic efflux pump increases quorum sensing mediated virulence .
Res Sq. 2024 Nov 12:rs.3.rs-5391023. doi: 10.21203/rs.3.rs-5391023/v1.
6
In vivo divergent evolution of cross-resistance to new β-lactam/β-lactamase inhibitor combinations in Pseudomonas aeruginosa following ceftazidime/avibactam treatment.
Infection. 2025 Apr;53(2):635-647. doi: 10.1007/s15010-024-02432-5. Epub 2024 Nov 8.
7
Monitoring of Pseudomonas aeruginosa mutational resistome dynamics using an enrichment panel for direct sequencing of clinical samples.
EBioMedicine. 2024 Oct;108:105367. doi: 10.1016/j.ebiom.2024.105367. Epub 2024 Sep 26.
8
Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria.
Commun Med (Lond). 2024 Aug 29;4(1):170. doi: 10.1038/s43856-024-00591-y.
9
Not all carbapenem-resistant Pseudomonas aeruginosa strains are alike: tailoring antibiotic therapy based on resistance mechanisms.
Curr Opin Infect Dis. 2024 Dec 1;37(6):594-601. doi: 10.1097/QCO.0000000000001044. Epub 2024 Sep 18.
10
Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing complex and difficult-to-treat resistance (DTR) infections: a single-center preliminary experience.
Front Microbiol. 2024 Jul 16;15:1432296. doi: 10.3389/fmicb.2024.1432296. eCollection 2024.
本文引用的文献
1
Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump.
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0008921. doi: 10.1128/AAC.00089-21.
2
The Building Blocks of Antimicrobial Resistance in : Implications for Current Resistance-Breaking Therapies.
Front Cell Infect Microbiol. 2021 Apr 16;11:665759. doi: 10.3389/fcimb.2021.665759. eCollection 2021.
3
Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00084-21.
4
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update.
Int J Antimicrob Agents. 2020 Dec;56(6):106196. doi: 10.1016/j.ijantimicag.2020.106196. Epub 2020 Oct 9.
5
Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance.
Clin Infect Dis. 2021 Dec 6;73(11):e4599-e4606. doi: 10.1093/cid/ciaa1306.
6
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Clin Infect Dis. 2021 Dec 6;73(11):e4539-e4548. doi: 10.1093/cid/ciaa803.
7
In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa.
J Antimicrob Chemother. 2020 Sep 1;75(9):2508-2515. doi: 10.1093/jac/dkaa206.
8
Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.02165-19.
9
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Clin Infect Dis. 2020 Apr 15;70(9):1799-1808. doi: 10.1093/cid/ciz530.
10
In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.
BMC Microbiol. 2019 Jul 4;19(1):150. doi: 10.1186/s12866-019-1522-7.
Zotero 插件